Nutex Health is trading 11.6% down now at $174.67 after a sharp reversal following two strong post-earnings sessions.
- August 6 results showed a major EPS beat, but revenue declined year over year.
- Profitability benefited substantially from lower arbitration-related costs and the HaloMD contract amendment.
- No new company-specific announcement or direct catalyst was identified; broader markets were nearly flat while healthcare remained positive.